Item Type | Name |
Academic Article
|
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
|
Academic Article
|
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
|
Academic Article
|
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
|
Academic Article
|
The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
|
Academic Article
|
An in vivo platform for translational drug development in pancreatic cancer.
|
Academic Article
|
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
|
Academic Article
|
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
|
Academic Article
|
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
|
Academic Article
|
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
|
Academic Article
|
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
|
Academic Article
|
Targeting EGFR in colorectal cancer.
|
Academic Article
|
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
|
Academic Article
|
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
|
Academic Article
|
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
|
Academic Article
|
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
|
Academic Article
|
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
|
Academic Article
|
TNF-blockade in patients with advanced hormone refractory prostate cancer.
|
Academic Article
|
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.
|
Academic Article
|
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
|
Academic Article
|
ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation.
|
Academic Article
|
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
|
Academic Article
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
|
Academic Article
|
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
|
Academic Article
|
Current status of SRC inhibitors in solid tumor malignancies.
|
Academic Article
|
Promising targets and drugs in development for colorectal cancer.
|
Academic Article
|
Longitudinal assessment of oxaliplatin-induced neuropathy.
|
Academic Article
|
Development of novel targeted agents in the treatment of metastatic colorectal cancer.
|
Academic Article
|
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
|
Academic Article
|
Oxaliplatin-induced neuropathy in colorectal cancer.
|
Academic Article
|
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
|
Academic Article
|
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a ?-secretase inhibitor and irinotecan in colorectal cancer.
|
Academic Article
|
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
|
Academic Article
|
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
|
Academic Article
|
Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer.
|
Academic Article
|
The development of regorafenib and its current and potential future role in cancer therapy.
|
Academic Article
|
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.
|
Academic Article
|
Recent advances in the pharmacological treatment of colorectal cancer.
|
Academic Article
|
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
|
Academic Article
|
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
|
Academic Article
|
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
|
Academic Article
|
Novel targets in solid tumors: MEK inhibitors.
|
Academic Article
|
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
|
Academic Article
|
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
|
Academic Article
|
No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system.
|
Academic Article
|
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
|
Academic Article
|
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
|
Academic Article
|
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
|
Academic Article
|
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
|
Academic Article
|
Novel agents in the treatment of metastatic colorectal cancer.
|
Academic Article
|
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
|
Academic Article
|
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
|
Academic Article
|
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
|
Academic Article
|
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
|
Academic Article
|
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
|
Academic Article
|
Recurrent pancreatic adenocarcinoma after pancreatic resection.
|
Academic Article
|
Patient-derived tumour xenografts as models for oncology drug development.
|
Academic Article
|
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
|
Academic Article
|
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
|
Academic Article
|
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
|
Academic Article
|
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
|
Academic Article
|
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
|
Academic Article
|
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
|
Academic Article
|
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
|
Academic Article
|
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
Concept
|
Biliary Tract Neoplasms
|
Concept
|
Cancer Care Facilities
|
Concept
|
Adrenal Cortex Neoplasms
|
Concept
|
Breast Neoplasms, Male
|
Concept
|
Anus Neoplasms
|
Concept
|
Esophageal Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Rectal Neoplasms
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Uveal Neoplasms
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Cancer Vaccines
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Kidney Neoplasms
|
Concept
|
Stomach Neoplasms
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Bile Duct Neoplasms
|
Concept
|
Neoplasms
|
Concept
|
Skin Neoplasms
|
Concept
|
Colonic Neoplasms
|
Concept
|
Gastrointestinal Neoplasms
|
Concept
|
Intestinal Neoplasms
|
Concept
|
Liver Neoplasms
|
Academic Article
|
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
|
Academic Article
|
Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma.
|
Academic Article
|
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
|
Academic Article
|
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a ?-secretase inhibitor, in a preclinical colorectal explant model.
|
Academic Article
|
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
|
Academic Article
|
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
|
Academic Article
|
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
|
Academic Article
|
Colon cancer, version 3.2014.
|
Academic Article
|
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
|
Academic Article
|
Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical cancer.
|
Academic Article
|
Panitumumab in the treatment of colon cancer: A biomarker dilemma.
|
Academic Article
|
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
|
Academic Article
|
Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers.
|
Academic Article
|
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014.
|
Academic Article
|
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
|
Academic Article
|
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
|
Academic Article
|
A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
|
Academic Article
|
ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/?-Catenin, Notch and PI3K/Akt Signaling Pathways.
|
Academic Article
|
Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
|
Academic Article
|
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
|
Academic Article
|
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
|
Academic Article
|
Rectal Cancer, Version 2.2015.
|
Academic Article
|
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
|
Academic Article
|
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
|
Academic Article
|
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
|
Academic Article
|
Targeting the WNT Signaling Pathway in Cancer Therapeutics.
|
Academic Article
|
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
|
Academic Article
|
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
|
Academic Article
|
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
|
Academic Article
|
Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma.
|
Academic Article
|
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
|
Academic Article
|
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
|
Academic Article
|
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
|
Academic Article
|
Therapeutic Approaches to RAS Mutation.
|
Academic Article
|
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
|
Academic Article
|
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
|
Academic Article
|
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
|
Academic Article
|
Topoisomerase IIa mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.
|
Academic Article
|
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
|
Academic Article
|
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.
|
Academic Article
|
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
|
Academic Article
|
Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.
|
Academic Article
|
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
|
Academic Article
|
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
|
Academic Article
|
Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer.
|
Grant
|
Evaluation of Src Inhibition in Pancreas Cancer
|
Grant
|
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
|
Grant
|
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
|
Grant
|
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
|
Academic Article
|
Systemic Management of Colorectal Cancer.
|
Academic Article
|
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
|
Academic Article
|
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
|
Academic Article
|
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
|
Academic Article
|
Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database.
|
Academic Article
|
Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
|
Academic Article
|
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
|
Academic Article
|
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
|
Academic Article
|
Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer.
|
Academic Article
|
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
|
Academic Article
|
A Blueprint to Advance Colorectal Cancer Immunotherapies.
|
Academic Article
|
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
|
Academic Article
|
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
|
Academic Article
|
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
|
Academic Article
|
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
|
Academic Article
|
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
|
Academic Article
|
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
|
Academic Article
|
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.
|
Academic Article
|
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
|
Academic Article
|
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
|
Academic Article
|
CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.
|
Academic Article
|
Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
|
Academic Article
|
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.
|
Academic Article
|
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
|
Academic Article
|
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
|
Concept
|
Triple Negative Breast Neoplasms
|
Academic Article
|
Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
|
Academic Article
|
NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer.
|
Academic Article
|
Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
|
Academic Article
|
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
|
Academic Article
|
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
|
Academic Article
|
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
|
Academic Article
|
Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
|
Academic Article
|
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
|
Academic Article
|
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.
|
Academic Article
|
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
|
Academic Article
|
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
|
Academic Article
|
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
|
Academic Article
|
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
|
Academic Article
|
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
|
Academic Article
|
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
|
Academic Article
|
Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
|
Academic Article
|
Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.
|
Academic Article
|
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
|
Academic Article
|
Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.
|
Academic Article
|
Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
|
Academic Article
|
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers.
|
Academic Article
|
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
|
Academic Article
|
Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study.
|
Academic Article
|
Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases.
|
Academic Article
|
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
|
Academic Article
|
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
|
Academic Article
|
Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma.
|
Academic Article
|
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
|
Academic Article
|
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
|
Academic Article
|
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.
|
Academic Article
|
Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response.
|
Academic Article
|
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
|
Academic Article
|
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.
|
Academic Article
|
Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer.
|
Academic Article
|
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
|
Academic Article
|
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.
|
Academic Article
|
Advances in the management of pancreatic cancer.
|